World News Insights
1-3 Minute Gist

Browse Articles or use Lyrarc's US patented "Groups" and "Links" for new insights. A Lyrarc Group of Articles on a topic gives insights into particular angles shown in the Group Title. A Lyrarc Link shows more specific insights for 2 articles.

All Topics Articles

LyrArc brings in selected articles from many of the world's top publications.

Articles are selected by experts and you can see the gist of the important articles.

Teva Deal Probe Gets Extension

2 Groups   
Wall Street Journal - 12.03.2008 Original article ›
Wsj Print, Wsj, Print
LyrArc Article Gist
Teva Pharmaceutical's acquisition of generic drug maker Barr Pharmaceutical for $7.46 billion to strengthen its position in emerging markets and expand its product portfolio.
Read LyrArc gist ›

Wyeth Loses Bout in Fight on a Generic

3 Groups   
New York Times - 09.08.2007 Original article ›
Stephanie Saul, Stephanie, Saul
LyrArc Article Gist
Protonix or Pantoprazole Wyeth's third best selling drug with sales of $1.8 billion has patent that expires in July 2010. Now a judge has ruled that Teva Pharmaceutical can introduce its generic version of this drug, Teva had filed a suit challenging the patent's validity and the judge ruled rejecting Wyeth's request to block the generic version from being marketed. Pantoprazole is used to treat severe inflammation of the esophagus from excess acid production.
Read LyrArc gist ›

Branded Drugs Settling More Generic Suits

2 Groups   
Wall Street Journal - 01.17.2006 Original article ›
Leila Abboud, Leila, Abboud

Outsourcing the Drug Industry

7 Groups   
BusinessWeek - 09.04.2008 Original article ›
Pete Engardio, Pete, Engardio, Arlene Weintraub, Arlene, Weintraub
LyrArc Article Gist
Indian companies and the speed and effective ways they do research offers a new model for western pharmaceutical companies and many of them are collaborating and setting up partnerships to discover and benefit from new drugs.
Read LyrArc gist ›

Stefano Pessina, the Man Shaking Up U.S. Pharmacy Distribution

6 Groups   
Wall Street Journal - 05.20.2013 Original article ›
Timothy W. Martin, Timothy, W., Martin

The High Cost of Asthma in America

4 Groups   
New York Times - 10.15.2013 Original article ›
Letters
LyrArc Article Gist
Letters to the editor on the excessive cost of asthma medications, and the faulty permitting of re-patenting of asthma inhalers as a result of a environmental law related to ozone layer. The re-patenting resulted in the asthma inhalers commonly used being priced much higher than before. The letters from doctors and nursing practitioners details their alarm at what is happening in asthma inhaler pricing that hurts the middle class and the poor in America.
Read LyrArc gist ›

CEO who raised price of old pill more than $700 calls journalist a ‘moron’ for asking why - The Washington Post

5 Groups   
Washington Post - 09.22.2015 Original article ›
Ariana Eunjung Cha, Ariana, Eunjung, Cha

Amgen and Watson to Work Together on Generic Drugs

4 Groups   
New York Times - 12.19.2011 Original article ›
Andrew Pollack, Andrew, Pollack

Glaxo Tries Biotech Model to Spur Drug Innovations

1 Links 7 Groups   
Wall Street Journal - 07.01.2010 Original article ›
Jeanne Whalen, Jeanne, Whalen
LyrArc Article Gist
Dr Kevin Lee, a British neuroscientist, heads EpiNova, a 60 person unit within Glaxo's R&D department. Lee founded two biotech startups before joining Glaxo. The smaller units called Discovery Performance Units are Glaxo's way of creating biotech startup like units which it is hoped will produce better results. The 36 DPU's in Glaxo R&D are given 3 year budgets and flexibility to make their own decisions for drug research. The large bureaucracy, scientists not working across fields and an older mindset are seen as obstacles in the search for new drugs. EpiNova with its own logo operates in a a Glaxo facility, an hour north of London. Decisions are made faster, says EpiNova chemist Dr. Wilson, and the atmosphere is that of a startup willing to try new approaches quickly.
Read LyrArc gist ›

Amgen's Star Fades Amid Safety Questions

16 Groups   
Wall Street Journal - 04.10.2007 Original article ›
Marilyn Chase, Marilyn, Chase
LyrArc Article Gist
Two of Amgen's drugs that treat anemia in cancer and kidney-failure patients have questions raised about their safety and marketing. The two anemia drugs Epogen and Aranesp generate about half of Amgen's sales. THey now have ablack box warning placed on them by FDA requirements.
Read LyrArc gist ›

AARP Study Says Price of Popular Drugs Rose 26%

22 Groups   
New York Times - 03.06.2012 Original article ›
Katie Thomas, Katie, Thomas
LyrArc Article Gist
A study by AARP of 514 brand name and generic drugs between 2005 and 2009, shows that generic drug prices went down an average of 31% during this period, and brand name drug prices went up by 41%. One of the authors of the report says that it is important to look at individual drug prices and not studies showing total spending on drugs, because this is a significant cost for people paying out-of-pocket, It drives up insurance premiums, and pushes retirees into coverage gaps in Medicare Part D drug program. Analysts indicate pharmaceutical companies are increasing prices on drugs before patent expiration to get as much profit before the patents expire.
Read LyrArc gist ›

The Soaring Cost of a Simple Breath

9 Groups   
New York Times - 10.12.2013 Original article ›
Elisabeth Rosenthal, Elisabeth, Rosenthal

Large Price Jumps Reported for Small but Vital Drugs

12 Groups   
New York Times - 01.11.2010 Original article ›
Gardiner Harris, Gardiner, Harris
LyrArc Article Gist
According to the General Accountability Office inquiry, 28 drug products had price increases over 100% in 2000, in 2008 71 drug products had such large increases. Medicines like Adderall for attention deficit disorder, Inderal for chest pain, Sumycin for infections were in the list of 416 brand name drug products where makers or distributors raised prices at least once by 100% or more for period 2000-2008. As large pharmaceutical companies sold their marginally profitable drug products or small selling products to smaller companies, these smaller companies would immediately increase prices to recover the money they paid to the large pharmaceutical companies. 26 of the brand name products saw prices raised 10 fold. A third of the drugs with large price increases treat depression and disorders of the central nervous system.
Read LyrArc gist ›

Beneath Budget Battle, a Health-Spending Juggernaut

2 Links 14 Groups   
Wall Street Journal - 12.17.2012 Original article ›
Laura Meckler, Laura, Meckler
LyrArc Article Gist
Estimates show the 50 million Americans enrolled in Medicare today will increase to 80 million by 2030, according to the program's actuaries. Simple demographics as the baby boom generation ages is making controlling the deficit without controlling increase in health care costs as both sides in the fiscal cliff negotiations are attempting to do can only lead to defunding critical areas such as education, R&D and infrastructure, and breaching the safety net for lower income Americans. Health care spending took up 7% of GDP in 1960, increasing to 17.9% of GDP in 2010. Federal spending on healthcare has grown to about 25% in 2012 from 10% in 1960, and is projected to increase to about 33% in ten years by the Congressional Budget Office.
Read LyrArc gist ›

Mylan Reacts to EpiPen Backlash

12 Groups   
WSJ - 08.26.2016 Original article ›
Jonathan D. Rockoff
LyrArc Article Gist
EpiPen's price has jumped 550% over 8 years. Mylan Pharmaceuticals is dominant in the $1 billion market for treating serious allergic reactions. Mylan acquired reights to sell EPiPen in late 2007. A pack of two list price is now $608.61. Last Nov. Sanofi's competing product Auvi-Q was recalled giving Mylan price dominance. A problem for consumers is that EpiPen expires in one year. Mylan launched a campaign to make parents aware of the product for children with peanut and other allergies, and also lobbied the governments to make ready supply of EpiPens available in schools and other public places. Now the controversy over price increases, with Hillary Clinton citing this as an example of exorbitant pharmaceutical pricing, is likely to change the environment around EpiPen and other overpriced drugs or healthcare products.

Read LyrArc gist ›
Original article 6 minutes, gist 1 minute

Support LyrArc

We took a different way to help millions around the world build educated informed mindsets that affects and shapes their lives. For a future that is open, global and digital, with everyone having access to high quality information. We believe in the renewal of America, renewal of Europe, the renewal of India, the rest of Asia, Latin America and Africa. The renewal of our supply chains, health, education, infrastructure, as we rebuild our countries after the pandemic. Literacy and knowledge we believe cannot thrive and grow in a world of web bots, web crawlers, or AI. This requires human curiosity, human learning, and human imagination. We take as inspiration the saying- “One has to be free, and as broad as sky. One has to have a mind that is crystal clear, only then can truth shine in it.” Every contribution whether big or small is precious- in this crisis and ahead.

Support Lyrarc from as small as $1




Support LyrArc →


Copyright © 2006 - 2026 Intelilinks LLC
Terms and Conditions | Copyright Policy | Privacy Policy | Contact Us